Patient profiles and electrocardiographic changes
| Case | Age/sex | Arrhythmia | Underlying disease | EF (%) | Drug | Dose (mg/day) | Duration of treatment (days) | Amplitude of the maximum ST elevation | QRS width (secs) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | ||||||||||||||||||
| 1 | 70/M | PACs | None | 68 | P | 100 | 28 | 2.5 mm (V1, V2) | 0.09 | 0.11 | |||||||||
| 2 | 62/F | Paf | MVR | 62 | P | 150 | 14 | 3.9 mm (V2) | 0.1 | 0.12 | |||||||||
| 3 | 57/M | Paf | AMI, HT | 40 | P | 200 | 4 | 5.3 mm (V3) | 0.09 | 0.11 | |||||||||
| 4 | 57/M | Paf | None | 60 | F | 200 | 28 | 3.6 mm (V2) | 0.09 | 0.1 | |||||||||
| 5 | 73/M | Paf | SSS, HT | 66 | P1-150 | 150 | 14 | 2.7 mm (V1) | 0.11 | 0.12 | |||||||||
Paf, paroxysmal atrial fibrillation; PACs, premature atrial contractions; MVR, mitral valve replacement; AMI, acute myocardial infarction; HT, hypertension; SSS, sick sinus syndrome; EF, ejection fraction on echocardiography; P, pilsicainide; F, flecainide;
↵1-150 combined with digoxin.